Skip to content

Study · In vitro (cells) · 2006

1 result

Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.

Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR, Culler MD, Degli Uberti EC

The Journal of clinical endocrinology and metabolism28 Mar 2006Cited by 38 (Europe PMC)

PMID16569735 (opens in a new tab)DOI10.1210/jc.2006-0334 (opens in a new tab)PepBankPUB-16569735
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human medullary thyroid carcinoma cultures, lanreotide inhibition of calcitonin secretion distinguished responder and nonresponder groups.

    In plain wordsIn cells from human thyroid tumors, calcitonin secretion responses to lanreotide differed between groups.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedCalcitonin secretion response heterogeneity
    Study

    humann = 18

    medullary thyroid carcinoma primary cultures
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Two different groups were identified according to CT secretion inhibition by the clinically available SRIH analog, lanreotide.
    2 context sentences
    Summary · context
    Primary cultures were developed and tested with SRIH analogs interacting with SSTR1, SSTR2, and SSTR5.
    Summary · context
    We selected 18 MTC tumor samples, expressing SSTR1, SSTR2, and SSTR5.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.